Medical Use
Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat:
- -Patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
- -Adults with active lupus nephritis (LN) who are receiving standard therapy.
Limitations of Use: Benlysta’s efficacy has not been evaluated in patients with severe active central nervous system lupus, nor has it been assessed in combination with other biologics. Therefore, its use is not recommended in these scenarios.
Recommended Dosage:
- -Intravenous (IV) Administration:
- For adults with SLE or lupus nephritis and pediatric patients with SLE: The recommended IV dosage is 10 mg/kg at 2-week intervals for the first 3 doses, followed by 4-week intervals. Reconstitute, dilute, and administer as an IV infusion over 60 minutes. The infusion rate may be slowed or interrupted if an infusion reaction occurs. Stop the infusion immediately if a severe hypersensitivity reaction occurs.
- -Subcutaneous (SC) Administration:
- For adults with SLE: The recommended dosage is 200 mg once weekly, administered as an SC injection in the abdomen or thigh. SC dosing is not weight-based. If transitioning from IV to SC administration, give the first SC dose 1-4 weeks after the last IV dose.
- For adults with lupus nephritis: The recommended dosage is 400 mg (two 200 mg injections) once weekly for the first 4 doses, then 200 mg once weekly thereafter. Administer the dose via SC injection in the abdomen or thigh. Transition from IV to SC therapy can occur any time after completing the first 2 IV doses, with the first SC dose given 1-2 weeks after the last IV dose.
Warning & Precautions
Patients receiving immunosuppressive agents like Belimumab may develop serious and sometimes fatal infections. Weigh the risks and benefits before starting treatment in those with serious or chronic infections. If a new infection occurs during treatment, consider pausing therapy and closely monitor the patient.
Acute hypersensitivity reactions, including anaphylaxis and death, have been reported with Belimumab. Monitor patients during the infusion and for a suitable period afterward. Premedication may be considered as a preventive measure before IV dosing.
Assess the risk of depression and suicide based on the patient’s medical history and current psychiatric status before starting therapy, and continue monitoring throughout treatment. Advise patients (and caregivers, if applicable) to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts or behaviors, or other mood changes.
Belimumab has not been evaluated in combination with other biological therapies, including B-cell targeted therapies. Therefore, its use is not recommended alongside other biological treatments.
Documentation Availability
Documents required to import BENLYSTA to India?
BENLYSTA (belimumab) injections can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing BENLYSTA (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Benlysta®?
The generic name for Benlysta® is belimumab.
Who manufactures Benlysta®?
Benlysta® is manufactured by Human Genome Sciences, Inc.
Is Benlysta® approved by the FDA?
Yes, Benlysta® was approved by the FDA on March 10, 2011.
What is the dosage and form of Benlysta®?
Benlysta® is available as injections in two forms: 120 mg or 400 mg per vial for intravenous use, and 200 mg/mL for subcutaneous use.
What are the most common side effects of Benlysta®?
Common side effects include diarrhea, migraine, depression, fever, nasopharyngitis, bronchitis, pain in extremities, insomnia, pharyngitis, nausea, and injection site reactions (for subcutaneous administration).
How much does Benlysta® cost in India?
The cost of Benlysta® in India can vary. For legal procurement, you can reach out to Rx4u team.
What are the storage conditions for Benlysta®?
Store autoinjectors and prefilled syringes in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. Keep them in their original packaging until use to protect from light. Do not shake and keep away from heat and sunlight.
How to order Benlysta® online in India?
Benlysta® can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
